Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma
Metrics: PDF 474 views | HTML 408 views | ?
Yunchao Li1, Chunhua Zhao2, Zhibin Yu2, Jiarui Chen3, Xiaoling She4, Peiyao Li2, Changhong Liu2, Yan Zhang2, Jianbo Feng2, Haijuan Fu2, Bing Wang1, Lei Kuang1, Lei Li1, Guohua Lv1, Minghua Wu2
1Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
2Cancer Research Institute, School of Basic Medical Science, Central South University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Key Laboratory of Carcinogenesis, Ministry of Health, Changsha, Hunan, China
3Xiangya Nursing School, Central South University, Changsha, Hunan, China
4Pathology Department, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Guohua Lv, email: firstname.lastname@example.org
Minghua Wu, email: email@example.com
Keywords: miR-381, osteosarcoma, LRRC4, chemosensitivity
Received: April 09, 2016 Accepted: August 24, 2016 Published: September 06, 2016
Osteosarcoma (OS) is the most common primary bone malignancy with a poor prognosis for all races and both sexes. In this study, we found that miR-381 is a positive prognosis factor for OS patients that OS patients with a low expression of miR-381 had a longer survival time after surgical intervention, and miR-381 expression promotes MG-63 cell proliferation and cell invasion ability. Our results also showed a strong negative correlation between the expression of miR-381 and LRRC4 (brain relative specific expression gene) in OS tissues. This demonstrated that LRRC4 is a direct target gene of miR-381, and suppressing the expression of miR-381 increases the sensitivity of OS cells to chemotherapeutic drugs through the LRRC4-mediated mTOR pathway. In summary, miR-381 is an important biomarker in directing therapeutic intervention and predicting prognosis in OS patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.